SCHEMBL2009208

SCHEMBL2009208

Cc1ccccc1Cc1nsc(N2CCCNCC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
NCF1 P14598 2/20 0.41
ADRB1 P08588 3/20 0.40
HTR6 P50406 1/20 0.40
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNA4 P43681 1/20 0.38
OPRL1 P41146 1/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
HTR7 P34969 1/20 0.37
PRKCI P41743 2/20 0.37
HTR1A P08908 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2005879 0.95 LMNA (0.47) LMNAHTR2CHTR2BNCF1ADRB1
SCHEMBL2011983 0.86 HTR2B (0.43) HTR2CHTR2BNCF1HTR6SLC6A2
SCHEMBL2003762 0.85 HTR7 (0.45) LMNAHTR2CHTR2BADRB1HTR6
SCHEMBL2005372 0.83 CETP (0.47) HTR2CHTR2BNCF1HTR6MAPT
SCHEMBL3066582 0.81 DPP4 (0.45) LMNAHTR6MAPTMEN1KMT2A
SCHEMBL2011744 0.81 CNR1 (0.49) HTR2CHTR2BNCF1ADRB1HTR6
SCHEMBL2006686 0.80 HTR2B (0.46) HTR2CHTR2BHTR6SLC6A2SLC6A4
SCHEMBL2008870 0.80 HTR6 (0.39) LMNAHTR2CHTR2BHTR6MAPT
SCHEMBL2006517 0.80 HTR6 (0.48) LMNAHTR2CHTR2BADRB1HTR6
SCHEMBL2005415 0.79 HTR2C (0.45) HTR2CHTR2BNCF1ADRB1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed
EP-2094677-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV Remynd (BE) 2009-09-02 EP disclosed
WO-2008061781-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP LMNA 1913/4885HTR2C 1846/4885HTR2B 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.